Amylin CEO: Firm Can Do Better With Byetta
This article was originally published in The Pink Sheet Daily
Executive Summary
Diabetes drug so far has failed to catch on with primary-care docs.
You may also be interested in...
Amylin, Lilly Partnership Tested By Lilly GLP-1 Project
Byetta relationship is “the best it has ever been,” Amylin says, but impact of Lilly’s competitive research will need to be negotiated.
Amylin, Lilly Partnership Tested By Lilly GLP-1 Project
Byetta relationship is “the best it has ever been,” Amylin says, but impact of Lilly’s competitive research will need to be negotiated.
Byetta Scripts, LAR Progress Unaffected By Safety Scare, Amylin Says
FDA's review of a new monotherapy indication for Amylin's type 2 diabetes agent Byetta (exenatide) may provide the opportunity for updating the labeling to reflect a stronger warning on pancreatitis